Exposure to inhibitors of the renin‐angiotensin system is a major independent risk factor for acute renal failure induced by sucrose containing intravenous immunoglobulins. A case‐control study

Onuigbo, Macaulay

doi:10.1002/pds.2273

Cited by 3 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…inhibitors of the renin-angiotensin system [18,76,77]. Generally, re-assess all prescribed drugs, especially in elderly patients.…”

Section: Discussionmentioning

confidence: 99%

Intravenous Immunoglobulins: In-Depth Review of Excipients and Acute Kidney Injury Risk

Dantal

2013

Am J Nephrol

View full text Add to dashboard Cite

Background: Used in a variety of approved and off-label indications, there are several intravenous immunoglobulin (IVIG) preparations available which differ in the excipients (e.g. sucrose, glucose, maltose, D-sorbitol, glycine or L-proline) used to stabilize the protein in the solution. A very rare, but severe adverse drug reaction (ADR) reported with sucrose-stabilized IVIGs, acute renal failure, is well established, but the relative risks with sucrose-free IVIGs are unknown. Methods: Medline and Embase were searched for published data on ADRs involving the kidney, and DrugCite, a public database of >4,000,000 ADRs from the USA, was also searched. Renal impairment-associated ADRs and categories were summarized. Results: Compared with sucrose-containing IVIGs, reports of ADRs involving the kidney were relatively rare with sucrose-free IVIGs: 12 cases were published prior to February 28, 2012; incidences reported in DrugCite were also relatively low and similar among sucrose-free preparations. The incidence of hemolysis-related ADRs, a potential cause of secondary acute renal impairment, was higher with glycine- and L-proline-stabilized IVIGs. Reported incidences of renal impairment with sucrose-free IVIGs are similar between products and much lower than with sucrose-stabilized IVIGs. Conclusions: It is recommended that the choice of IVIG should be guided by the patient's medical history, present comorbidities and concomitant medications. Prospective studies with inclusion of creatinine values, as well as rigorous reporting of cases in the literature and/or via pharmacovigilance systems, are imperative to better define patient profiles.

show abstract

“…inhibitors of the renin-angiotensin system [18,76,77]. Generally, re-assess all prescribed drugs, especially in elderly patients.…”

Section: Discussionmentioning

confidence: 99%

Intravenous Immunoglobulins: In-Depth Review of Excipients and Acute Kidney Injury Risk

Dantal

2013

Am J Nephrol

View full text Add to dashboard Cite

show abstract

“…We sincerely thank MA Onuigbo for his interest shown in our original report . In his commentary, the author offered a major overview of the risk of acute renal failure (ARF) when exposed to angiotensin‐converting enzyme inhibitors (ACE‐Is) and angiotensin receptor antagonists (ARAs) in several medical conditions. This is a very useful comment, alerting to the need to temporarily stop ACE‐I or ARA in all clinical situations at risk of ARF.…”

mentioning

confidence: 99%

Reply to the commentary by Onuigbo on the article “Exposure to inhibitors of the renin–angiotensin system is a major independent risk factor for acute renal failure induced by sucrose‐containing intravenous immunoglobulins. A case–control study”

Moulis¹,

Sailler²,

Montastruc³

2012

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

Prise en charge des événements indésirables chez les patients sous traitement par immunoglobulines : recommandations pour la pratique clinique

Marie

Chérìn

Michallet

et al. 2017

La Revue de Médecine Interne

View full text Add to dashboard Cite

Exposure to inhibitors of the renin‐angiotensin system is a major independent risk factor for acute renal failure induced by sucrose containing intravenous immunoglobulins. A case‐control study

Cited by 3 publications

References 16 publications

Intravenous Immunoglobulins: In-Depth Review of Excipients and Acute Kidney Injury Risk

Intravenous Immunoglobulins: In-Depth Review of Excipients and Acute Kidney Injury Risk

Reply to the commentary by Onuigbo on the article “Exposure to inhibitors of the renin–angiotensin system is a major independent risk factor for acute renal failure induced by sucrose‐containing intravenous immunoglobulins. A case–control study”

Prise en charge des événements indésirables chez les patients sous traitement par immunoglobulines : recommandations pour la pratique clinique

Contact Info

Product

Resources

About